While the Targeted Radionuclide Therapy Market holds immense potential, it faces significant hurdles related to isotope supply security and infrastructure readiness. Radioactive isotopes, which are essential for these therapies, have short half-lives, requiring a highly efficient and time-sensitive supply chain. Manufacturers are currently investing in decentralized production models and...